Marcia Hall
About
Marcia Hall is a scholar working on Reproductive Medicine, Oncology and Surgery.
According to data from OpenAlex, Marcia Hall has authored 157 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Reproductive Medicine, 49 papers in Oncology and 38 papers in Surgery. Recurrent topics in Marcia Hall's work include Ovarian cancer diagnosis and treatment (49 papers), PARP inhibition in cancer therapy (18 papers) and Endometrial and Cervical Cancer Treatments (13 papers). Marcia Hall is often cited by papers focused on Ovarian cancer diagnosis and treatment (49 papers), PARP inhibition in cancer therapy (18 papers) and Endometrial and Cervical Cancer Treatments (13 papers). Marcia Hall collaborates with scholars based in United Kingdom, United States and Australia. Marcia Hall's co-authors include Gordon Peters, Emmanouíl Karteris, Gordon Rustin, Stewart Bates, Godefridus J. Peters, Sarah Benafif, Ioannis Kyrou, Harpal Randeva, Ann E. Taylor and Hardev Pall and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Annals of Internal Medicine.
In The Last Decade
Marcia Hall
155 papers receiving 3.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Marcia Hall United Kingdom | 30 | 1.4k | 1.2k | 580 | 467 | 399 | 157 | 3.7k | ||
| Claudio Orlando Italy | 42 | 1.6k 1.1× | 2.8k 2.2× | 472 0.8× | 460 1.0× | 685 1.7× | 177 | 6.3k | ||
| Georg J. Arnold Germany | 39 | 483 0.3× | 1.7k 1.4× | 497 0.9× | 649 1.4× | 415 1.0× | 153 | 4.0k | ||
| Susan Van Noorden United Kingdom | 41 | 804 0.6× | 1.8k 1.4× | 294 0.5× | 1.0k 2.2× | 502 1.3× | 130 | 5.2k | ||
| Toshio Mori Japan | 44 | 1.2k 0.8× | 4.3k 3.5× | 335 0.6× | 293 0.6× | 793 2.0× | 238 | 7.6k | ||
| Takahiro Taguchi Japan | 33 | 1.0k 0.7× | 1.8k 1.4× | 104 0.2× | 382 0.8× | 546 1.4× | 136 | 4.2k | ||
| Souichi Adachi Japan | 42 | 760 0.5× | 2.5k 2.0× | 161 0.3× | 310 0.7× | 931 2.3× | 306 | 6.1k | ||
| Hugh Mitchell United States | 29 | 382 0.3× | 1.3k 1.0× | 443 0.8× | 384 0.8× | 309 0.8× | 85 | 3.3k | ||
| Claus Oxvig Denmark | 53 | 783 0.6× | 3.1k 2.5× | 309 0.5× | 746 1.6× | 781 2.0× | 179 | 8.6k | ||
| Gerard J. te Meerman Netherlands | 34 | 559 0.4× | 1.6k 1.3× | 211 0.4× | 617 1.3× | 564 1.4× | 103 | 4.0k | ||
| Janice Y. Chou United States | 52 | 927 0.7× | 3.1k 2.5× | 152 0.3× | 868 1.9× | 883 2.2× | 235 | 8.3k |
Countries citing papers authored by Marcia Hall
Since
Specialization
Citations
This map shows the geographic impact of Marcia Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcia Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcia Hall more than expected).
Fields of papers citing papers by Marcia Hall
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Marcia Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcia Hall. The network helps show where Marcia Hall may publish in the future.
Co-authorship network of co-authors of Marcia Hall
This figure shows the co-authorship network connecting the top 25 collaborators of Marcia Hall. A scholar is included among the top collaborators of Marcia Hall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcia Hall. Marcia Hall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Nicum, Shibani, Rachel Austin, Linda Collins, et al.. (2024). Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer. British Journal of Cancer. 130(6). 941–950.
2.
Pignata, Sandro, Mariusz Bidziński, M.J. Rubio Pérez, et al.. (2024). 39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer. ESMO Open. 9. 103539–103539.
3.
Marth, Christian, Richard D. Moore, Mariusz Bidziński, et al.. (2024). Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study. Gynecologic Oncology. 190. S63–S64.
4.
D’Angelo, Armando, James W. Wood, U. Mukherjee, et al.. (2023). 800P Response to chemotherapy following PARP inhibition in UK ovarian cancer (OC) patients. Annals of Oncology. 34. S535–S535.
5.
Wyrwicz, Lucjan, Mark Saunders, Marcia Hall, et al.. (2023). AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiotherapy and Oncology. 185. 109669–109669.
6.
Khalique, Saira, et al.. (2023). Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: association with treatment outcomes. International Journal of Gynecological Cancer. 33(9). 1427–1433.
7.
Miller, Rowan, Andrew R. Clamp, Charlie Gourley, et al.. (2022). 2022-RA-1276-ESGO Pembrolizumab monotherapy for advanced clear cell gynaecological cancer: phase II PEACOCC trial. International Journal of Gynecological Cancer. 32. A316–A316.
8.
Oza, Amit M., Maria Del Pilar Estevez-Diz, Eva‐Maria Grischke, et al.. (2020). A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer. Clinical Cancer Research. 26(18). 4767–4776.
9.
Glynne‐Jones, Rob, Marcia Hall, & Irıs D. Nagtegaal. (2020). The optimal timing for the interval to surgery after short course preoperative radiotherapy (5 ×5 Gy) in rectal cancer - are we too eager for surgery?. Cancer Treatment Reviews. 90. 102104–102104.
10.
Morrison, Jo, Peter Baldwin, Lynn Buckley, et al.. (2020). British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: Recommendations for practice. European Journal of Obstetrics & Gynecology and Reproductive Biology. 252. 502–525.
11.
Katsuta, Eriko, Kazuaki Takabe, George Pados, et al.. (2020). H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall Survival. Journal of Clinical Medicine. 9(9). 2844–2844.
12.
Carter, Thomas J., et al.. (2020). Identification of Cancer-Associated Circulating Cells in Anal Cancer Patients. Cancers. 12(8). 2229–2229.
13.
Katopodis, Periklis, Juhi Kumar, Vladimir Anikin, et al.. (2019). Kinase Inhibitors and Ovarian Cancer. Cancers. 11(9). 1357–1357.
14.
Winfield, Jessica, David Dolling, Marcia Hall, et al.. (2019). Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. Radiology. 293(2). 374–383.
15.
Blagden, Sarah P., Anne Hamilton, Linda Mileshkin, et al.. (2018). Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. Clinical Cancer Research. 25(5). 1472–1478.
16.
McNeish, Iain A., JA Ledermann, Lisa M. James, et al.. (2014). A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Annals of Oncology. 25(10). 1988–1995.
17.
Banerjee, Susana, James Paul, Christopher J.M. Williams, et al.. (2012). A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Annals of Oncology. 24(3). 679–687.
18.
Barker, Douglas C., Rohini Sharma, Angus McIndoe, et al.. (2009). An Unusual Case of Sex Cord Tumor With Annular Tubules With Malignant Transformation in a Patient With Peutz-Jeghers Syndrome. International Journal of Gynecological Pathology. 29(1). 27–32.
19.
Hall, Marcia & Robert T. Johnson. (1996). The role of DNA repair in the prevention of cancer. Molecular Aspects of Medicine. 17(3). 235–383.
20.
Weller, A., Marcia Hall, & Sally A. Huber. (1992). Polyclonal immunoglobulin therapy protects against cardiac damage in experimental coxsackievirus-induced myocarditis. European Heart Journal. 13(1). 115–119.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Claudio Orlando Breakdown of academic impact, for papers by Georg J. Arnold Breakdown of academic impact, for papers by Susan Van Noorden Breakdown of academic impact, for papers by Toshio Mori Breakdown of academic impact, for papers by Takahiro Taguchi Breakdown of academic impact, for papers by Souichi Adachi Breakdown of academic impact, for papers by Hugh Mitchell Breakdown of academic impact, for papers by Claus Oxvig Breakdown of academic impact, for papers by Gerard J. te Meerman Breakdown of academic impact, for papers by Janice Y. Chou